Search

Your search keyword '"Lonero, A."' showing total 5 results
Start Over Author "Lonero, A." Journal journal of endocrinological investigation
5 results on '"Lonero, A."'

1. Isolated childhood growth hormone deficiency: a 30-year experience on final height and a new prediction model.

Author

Lonero, Antonella, Giotta, Massimo, Guerrini, Giulia, Calcaterra, Valeria, Galazzi, Elena, Iughetti, Lorenzo, Cassio, Alessandra, Wasniewska, Gabriela Malgorzata, Mameli, Chiara, Tornese, Gianluca, Salerno, Mariacarolina, Cherubini, Valentino, Caruso Nicoletti, Manuela, Street, Maria Elisabeth, Grandone, Anna, Giacomozzi, Claudio, Faienza, Maria Felicia, Guzzetti, Chiara, Bellone, Simonetta, and Parpagnoli, Maria

Published
2022
Full Text
View/download PDF

2. Growth hormone treatment improves final height and nutritional status of children with chronic kidney disease and growth deceleration

Author

Dello Strologo L, Cavallo L, Cappa M, Mario Giordano, Faienza Mf, Maurizio Delvecchio, Bizzarri C, and Lonero A

Subjects
Male, medicine.medical_specialty, Deceleration, Endocrinology, Diabetes and Metabolism, 030232 urology & nephrology, Physiology, Nutritional Status, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Internal medicine, medicine, Humans, 030212 general & internal medicine, Renal Insufficiency, Chronic, Child, Growth Disorders, Growth retardation, Human Growth Hormone, business.industry, Human growth hormone, Final height, Case-control study, Nutritional status, Prognosis, medicine.disease, Body Height, Growth hormone treatment, Case-Control Studies, Female, Complication, business, Follow-Up Studies, Kidney disease
Abstract

Growth retardation is a common complication of chronic kidney disease (CKD) in children. Treatment with recombinant human growth hormone (rhGH) has been used to help short children with CKD to attain a height more in keeping with their age group, but the scientific evidence regarding the effect of rhGH on final height is scarce. Final heights of children with CKD receiving rhGH treatment (cases) were compared with final heights of a matched cohort of children with CKD that did not receive rhGH therapy (controls). Sixty-eight rhGH-treated cases (44 boys) were compared with 92 untreated controls (60 boys). Mean duration of rhGH therapy was 4.2 ± 0.9 years; rhGH dose was 0.3 ± 0.07 mg/kg/week. Height SDS at baseline was lower in rhGH-treated patients than in controls (−2.00 ± 1.02 versus −0.96 ± 1.11, p

Published
2017
Full Text
View/download PDF

5. Efficacy and safety of growth hormone treatment in children with short stature: the Italian cohort of the GeNeSIS clinical study

Author

Cappa, M., Iughetti, L., Loche, S., Maghnie, M., Vottero, A, GeNeSIS National Board on behalf of the GeNeSIS Italian Investigators, Franco, Antoniazzi, Luciano, Beccaria, Sergio, Bernasconi, Domenico, Caggiano, Manuela, Caruso-Nicoletti, Alessandra, Catucci, Francesco, Chiarelli, Stefano, Cianfarani, Annarita, Colucci, Francesca De Rienzo, Raffaele Di Pumpo, Alessandra Di Stasio, Giovanni, Farello, Leonardo, Felici, Pasquale, Femiano, Luigi, Garagantini, Claudia, Giavoli, Nellaaugusta, Greggio, Laura, Guazzarotti, Daniela, Larizza, Mariarosaria, Licenziati, Antonella, Lonero, Mariacristina, Maggio, Alberto, Marsciani, Patrizia, Matarazzo, Laura, Mazzanti, Beatrice, Messini, Flavia, Napoli, Annamaria, Pasquino, Laura, Perrone, Sabrina, Pilia, Alba, Pilotta, Marzia, Piran, Gabriella, Pozzobon, Predieri, Barbara, Michele, Sacco, Mariacarolina, Salerno, Antonina, Tirendi, Graziamaria, Ubertini, Silvia, Vannelli, Malgorzata, Wasniewska, Maria, Zampolli, Martina, Zanotti, Gianvincenzo, Zuccotti, Cappa, M., Iughetti, L., Loche, S., Maghnie, M., Vottero, A, Salerno, Mariacarolina, Vottero, A.* Antoniazzi F, Beccaria L, Bernasconi S, Caggiano D, Caruso-Nicoletti M, Catucci A, Chiarelli F, Cianfarani S, Colucci AR, De Rienzo F, Di Pumpo R, Di Stasio A, Farello G, Felici L, Femiano P, Garagantini L, Giavoli C, Greggio NA, Guazzarotti L, Larizza D, Licenziati MR, Lonero A, Maggio MC, Marsciani A, Matarazzo P, Mazzanti L, Messini B, Napoli F, Pasquino AM, Perrone L, Pilia S, Pilotta A, Piran M, Pozzobon G, Predieri B, Sacco M, Salerno M, Tirendi A, Ubertini G, Vannelli S, Wasniewska M, Zampolli M, Zanotti M, Zuccotti G, Vottero, A., and Perrone, Laura

Subjects
Male, Pediatrics, Endocrinology, Diabetes and Metabolism, Turner Syndrome, Pediatric GH treatment, Growth, Clinical study, 0302 clinical medicine, Endocrinology, Turner syndrome, 030212 general & internal medicine, Prospective Studies, Prospective cohort study, Child, Final height, Safety, Short stature, Human Growth Hormone, Diabetes and Metabolism, Growth hormone treatment, Treatment Outcome, Italy, Child, Preschool, Cohort, Original Article, Female, Patient Safety, medicine.symptom, Human, medicine.medical_specialty, Adolescent, 030209 endocrinology & metabolism, Dwarfism, Neuroendocrinology, Body Height, Dwarfism, Pituitary, Humans, 03 medical and health sciences, medicine, Preschool, business.industry, medicine.disease, Prospective Studie, Pituitary, Observational study, Final height, Growth, Pediatric GH treatment, Safety, Short stature, Endocrinology, Diabetes and Metabolism, Endocrinology, business
Abstract

Purpose: We examined auxological changes in growth hormone (GH)-treated children in Italy using data from the Italian cohort of the multinational observational Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS) of pediatric patients requiring GH treatment. Methods: We studied 711 children (median baseline age 9.6 years). Diagnosis associated with short stature was as determined by the investigator. Height standard deviation score (SDS) was evaluated yearly until final or near-final height (n = 78). Adverse events were assessed in all GH-treated patients. Results: The diagnosis resulting in GH treatment was GH deficiency (GHD) in 85.5 % of patients, followed by Turner syndrome (TS 6.6 %). Median starting GH dose was higher in patients with TS (0.30 mg/kg/week) than patients with GHD (0.23 mg/kg/week). Median (interquartile range) GH treatment duration was 2.6 (0.6–3.7) years. Mean (95 % confidence interval) final height SDS gain was 2.00 (1.27–2.73) for patients with organic GHD (n = 18) and 1.19 (0.97–1.40) for patients with idiopathic GHD (n = 41), but lower for patients with TS, 0.37 (−0.03 to 0.77, n = 13). Final height SDS was >−2 for 94 % of organic GHD, 88 % of idiopathic GHD and 62 % of TS patients. Mean age at GH start was lower for organic GHD patients, and treatment duration was longer than for other groups, resulting in greater mean final height gain. GH-related adverse events occurred mainly in patients diagnosed with idiopathic GHD. Conclusions: Data from the Italian cohort of GeNeSIS showed auxological changes and safety of GH therapy consistent with results from international surveillance databases.

Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results